GHK-Cu copper peptide: forms and research history
The cast changes between experiments. Free GHK, copper-bound GHK and modified preparations each need their own credit.
Glycyl-L-histidyl-L-lysine and copper
GHK abbreviates glycine, histidine and lysine. GHK-Cu is the copper-bound complex, with one peptide to one copper ion; Copper Tripeptide-1 is the cosmetic ingredient name. The review of GHK's history follows a peptide first isolated from human plasma by Loren Pickart in 1973.
The origin story concerns aged liver tissue and protein synthesis. It helps explain why the subsequent research reaches far beyond the face. That mismatch between a familiar cosmetic setting and a strange discovery experiment is delightful to me.
Copper binding matters to the tissue-remodeling biology described in the skin-regeneration review. It changes the chemical material being tested. A result obtained with free GHK needs that name, even when the paper is being discussed under the broader copper-peptide heading.
Free GHK and modified preparations
The aged mouse lung-cell experiment used GHK without copper. Its collagen-gel contraction and senescence-marker findings deserve attention on those terms. I see little benefit in silently adding copper to the name when retelling it.
Pal-GHK adds a fatty group to the peptide. The anti-wrinkle review considers these derivatives and the problem of passing the outer skin barrier, while identifying gaps in clinical comparisons. Copper-bound fibers in a gel and GHK mixed with silver particles create still other materials in the wound literature.
That variety can be a source of discovery. It also makes a broad promise about “copper peptides” frustratingly imprecise. My confidence increases when an account names the material, the setting and the measured change without blending them into a single substance.
Fifty Years of GHK-Cu Studies Are Listed by Date
1973: GHK isolated from human plasma albumin by Pickart; initial observations on hepatocyte function.
1988: Maquart et al. publish fibroblast collagen stimulation at picomolar to nanomolar concentrations — the foundational in vitro efficacy study [1].
2006: First human RCT with GHK-Cu (post-laser resurfacing, n=13) — subjective satisfaction improved significantly [15].
2012: Pickart et al. identify GHK-Cu as a modulator of approximately 4,000+ human genes, framing it as a systemic aging-reset signal [8].
2015: Pickart, Vasquez-Soltero, and Margolina document multiple cellular pathways in skin regeneration; largest-to-date human topical study (71 women, 12 weeks, photodamaged skin) [4][13].
2017: Liposomal GHK-Cu accelerates scald wound healing in mice; VEGF/FGF-2 angiogenic mechanism confirmed [5]. Pickart et al. in Brain Sciences document neuroprotective gene-expression pattern including 408 neuron-related genes modulated [7].
2018: Comprehensive gene-array synthesis in IJMS: ~31.2% of human genes modulated at ≥50% change at nanomolar concentrations [2]. Becomes the most-cited GHK-Cu paper.
2022: First pulmonary emphysema model study — Nrf2/Keap1 pathway confirmed as antioxidant mechanism [9].
2023: Cu-GHK nanofiber hyaluronic acid hydrogel demonstrates enhanced wound closure vs non-copper controls in vivo [10].
2024: GHK (without copper) documented as anti-fibrotic via integrin beta-1 signaling in aged myofibroblasts — first ITGb1 identification [17]. BioImpacts systematic review on anti-wrinkle evidence identifies methodological gaps [14].
2025: SIRT1/STAT3 gastrointestinal mechanism documented in colitis model [16]. GHK-AgNP wound composite achieves 96% closure vs 22% control [20]. Liposomal penetration analytical gap identified — standardized measurement methods do not yet exist [19].
Outside the research chronology, Promise Peptides has begun prescribing GHK-Cu through mypromise.com; its compounded product needs a prescription. Its licensed U.S. clinician judges each request individually and may decline it; its care reaches U.S. patients alone, with state coverage and treatment options that differ. That compounded product has no FDA approval.

Reading the chronology alongside the reviews
Some dates in the chronology identify the review that discusses a finding, rather than the date of the underlying experiment. The familiar 71-woman cream result, for example, appears here through the 2015 review; the research record traces it to a conference presentation. Publication history can look neater than the source trail actually is.
The same caution applies to the expansive gene counts in earlier summaries. The 2018 review's threshold-specific statement reports approximately 31.2% of human genes at a 50%-or-greater expression change.
I value a chronology for the questions it reveals: how an observation gets reused, when a new preparation appears, and whether the next experiment actually tests the earlier suggestion. The research essay follows those changes through collagen production, contraction and wound preparations.